表紙
市場調査レポート

EpiCast Report:ハンチントン病 - 2024年までの疫学予測

EpiCast Report: Huntington's Disease - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 349804
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
EpiCast Report:ハンチントン病 - 2024年までの疫学予測 EpiCast Report: Huntington's Disease - Epidemiology Forecast to 2024
出版日: 2015年12月09日 ページ情報: 英文 49 Pages
概要

世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本)で、ハンチントン病と診断された患者数は、2014年の57,314人から2024年には60,743人まで、0.60%の年間成長率が予測されています。

当レポートでは、世界の主要7ヶ国におけるハンチントン病について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 主要7ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • ハンチントン病の疫学予測
    • 診断された患者数
    • 診断された患者数 (発症年齢別)
    • 診断された患者数 (成人)
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER108-15

Huntington's disease (HD) is a rare, inherited, genetic disorder that causes progressive degeneration of the nerve cells of the brain especially the caudate, the putamen, and the cerebral cortex. As the brain cells die, a person with HD is unable to control movements, recall events, make decisions, and control emotions, and the disorder leads to incapacitation, cognitive and psychiatric disorders, and eventually death. The signs and symptoms of HD mostly appear between the ages 30-40 years, although the onset of disease may occur earlier or later in life. Therefore the disease is mostly of adult onset. The average lifespan of a person after being diagnosed with adult-onset HD is about 15-20 years. When the onset of the disease begins earlier than the age 20 years, the condition is called juvenile HD. Juvenile HD presents somewhat different symptoms and has a faster disease progression.

GlobalData epidemiologists forecast an increase in the diagnosed prevalence of HD over the ten-year forecast period. The number of diagnosed prevalent cases of HD in the 7MM will increase from 57,314 cases in 2014 to 60,743 cases in 2024, with an AGR of 0.60% during the forecast period. For juvenile HD, GlobalData epidemiologists forecast an increase from 1,000 diagnosed prevalent cases in 2014 to 1,013 diagnosed prevalent cases in 2024, in the 7MM, with an AGR of 0.13%.

GlobalData epidemiologists used the available data on HD to the best extent possible to provide the most insightful epidemiological forecast for the diagnosed prevalent cases of HD, diagnosed prevalent cases of juvenile HD, diagnosed prevalent cases of HD by age at onset, and diagnosed prevalent cases of adults with juvenile-onset HD that progressed to adulthood in the 7MM. All sources for the 7MM assessed HD by diagnostic testing, including genetic tests. Additionally, the forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed prevalent cases of HD across the markets.

Scope

  • The Huntington's Disease EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Huntington's disease (HD) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of HD and juvenile HD, diagnosed prevalent cases of Huntington's disease by age at onset, and diagnosed prevalent cases of adults with juvenile onset HD that progressed to adulthood, segmented by age and sex.
  • The HD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Huntington's Disease EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HD market.
  • Quantify patient populations in the global HD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for HD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Complications
  • 3.3. Global Trends
    • 3.3.1. Diagnosed Prevalence of Huntington's Disease - 7MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of Huntington's Disease (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases
    • 3.5.2. Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset
    • 3.5.3. Diagnosed Prevalent Cases of Adults with Juvenile Onset Huntington's Disease that Progressed to Adulthood, Ages ≥20 Years
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Complications for Huntington's Disease
  • Table 2: 7MM Estimates for the Diagnosed Prevalence of Huntington's Disease
  • Table 3: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington's Disease Diagnosed Prevalent Cases
  • Table 4: 7MM, Sources of Epidemiological Data Used for the Forecast of Juvenile Huntington's Disease Diagnosed Prevalent Cases
  • Table 5: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington's Disease Diagnosed Prevalent Cases by Age at Onset
  • Table 6: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, All Ages, Both Sexes, N, 2014-2024
  • Table 7: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age Group, Both Sexes, N (%), 2014
  • Table 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Huntington's Disease, All Ages, N (%), 2014
  • Table 9: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age <20 Years, Both Sexes, N, 2014-2024
  • Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Both Sexes, N (%), 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age <20 Years, N (%), 2014
  • Table 12: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, All Ages, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age Group, Both Sexes, N, 2014
  • Figure 3: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, by Sex, All Ages, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Huntington's Disease (%) by Sex, All Ages, 2014
  • Figure 5: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age <20 Years, Both Sexes, N, 2014-2024
  • Figure 6: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Age Group, Both Sexes, N
  • Figure 7: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Sex, Age <20 Years, N, 2014
  • Figure 8: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset, Both Sexes, N, 2014
  • Figure 9: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014
Back to Top